subject: EGFR Gene Signature May Predict Prognosis and Guide Treatment in Lung Cancer [print this page] EGFR Gene Signature May Predict Prognosis and Guide Treatment in Lung Cancer
The BATTLE I trial is part of a set of studies that are examining the genetic profiles of individual tumors and then assigning therapies that offer the best benefits on the basis of the tumor's unique characteristics. "The EGFR-mutation signature will be evaluated as a predictor of response in the BATTLE I trial," said Dr. Saintigny, adding that they will be presenting those results later this year at the annual meeting of the American Society of Clinical Oncology.
welcome to Insurances.net (https://www.insurances.net)
